Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cannara Biotech's Enterprise Value is C$211.8 Mil.
Cannara Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 was C$19.4 Mil. Therefore, Cannara Biotech's EV-to-OCF for today is 10.91.
The historical rank and industry rank for Cannara Biotech's EV-to-OCF or its related term are showing as below:
TSX:LOVE'
s EV-to-OCF Range Over the Past 10 Years
Min: -254.17 Med: -7.12 Max: 92.52
Current: 10.91
During the past 8 years, the highest EV-to-OCF of Cannara Biotech was 92.52. The lowest was -254.17. And the median was -7.12.
TSX:LOVE's EV-to-OCF is ranked worse than 51.39% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.55
vs TSX:LOVE: 10.91
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cannara Biotech's PE Ratio (TTM) for today is calculated as:
Cannara Biotech's share price for today is C$1.99.
Cannara Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cannara Biotech EV-to-OCF Related Terms
Cannara Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's EV-to-OCF falls into.
Cannara Biotech's current Enterprise Value is C$211.8 Mil.
Cannara Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$19.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (TSX:LOVE) has a EV-to-OCF of 10.91 as of Aug. 31, 2026. According to the industry distribution chart, Cannara Biotech ranks #517 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Cannara Biotech's EV-to-OCF too high?
Cannara Biotech's current EV-to-OCF is 10.91. The Drug Manufacturers industry median EV-to-OCF is 10.55. Cannara Biotech's value of 10.91 is 3.4% above this industry median. Based on the distribution chart, Cannara Biotech ranks #517 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #517 out of 1006 companies for EV-to-OCF. This places Cannara Biotech in the lower half of its industry. The industry median EV-to-OCF is 10.55. Cannara Biotech's value of 10.91 is 3.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.55, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current EV-to-OCF of 10.91 is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current EV-to-OCF is 10.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (TSX:LOVE) is currently considered Modestly Overvalued. The stock's GF Value™ is C$1.69, compared to a current price of C$1.99 — trading 17.8% above its estimated fair value. The current EV-to-OCF is 10.91 and 3.4% above the Drug Manufacturers industry median of 10.55. Cannara Biotech's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cannara Biotech (TSX:LOVE), the current EV-to-OCF is 10.91 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (TSX:LOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of C$1.99 is trading 17.8% above its estimated GF Value™ of C$1.69.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for TSX:LOVE:
EV-to-OCF: 10.91
GF Value™: C$1.69 vs. price of C$1.99 (17.8% above fair value)
Industry Position: 3.4% above the Drug Manufacturers median (#517 of 1006)
No single metric tells the full story. See the TSX:LOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
87GF Score
Get the complete analysis for TSX:LOVE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:LOVE has been successfully added to your 
